Subscribe free

HPB & Spleen ·

Significant Survival Benefit of Multimodality Treatment in Gallbladder Neuroendocrine Neoplasms

Gallbladder neuroendocrine neoplasms (GB NENs) are predominantly represented by neuroendocrine carcinomas. Outcomes analysis of 147 patients revealed a median overall survival (OS) of 6.14 months, with significant improvement to 20.20 months for those who received multimodality treatment versus 4.00 months for those who did not. These findings highlight the efficacy of multimodality approaches in improving survival outcomes for patients with GB NENs, emphasizing the need for further advances in systemic therapy.

Journal Article by Nandy K, Patkar S (…) Goel M et 4 al. in J Surg Oncol

© 2024 Wiley Periodicals LLC.

read the whole article in J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →